Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1053

Sort by

Sort Order Select

Journal Articles

Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis

Xiaotian Zhang, Xinyu Wang, Xue Qing David Wang, Jianzhong Su, Nagireddy Putluri, Ting Zhou, Ying Qu, Mira Jeong, Anna Guzman, Carina Rosas, Yun Huang, Arun Sreekumar, Wei Li, Margaret A. Goodell

Blood (2020) 135 (11): 845–856.

https://doi.org/10.1182/blood.2019003330

Published: 2020

Includes: Supplemental data

Journal Articles

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms

Blood (2020) 135 (3): 191–207.

https://doi.org/10.1182/blood.2019895326

Published: 2020

Includes: Supplemental data

Journal Articles

Dual Epigenetic Agents Plus Rituximab-Gemcitabine-Oxaliplatin As a Salvage Treatment in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Changju Qu, PhD, Nana Ping, MD, PhD, Danqing Kong, MD, Fan Xia, MD, Depei Wu, MD PhD, Zhengming Jin, MD

Blood (2019) 134 (Supplement_1): 5338.

https://doi.org/10.1182/blood-2019-128111

Published: 2019

Journal Articles

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Harish Kumar, PhD, Ujjal Kumar Mukherjee, PhD, Li Chen, PhD, Amit Kumar Mitra, PhD MSc, BSc

Blood (2019) 134 (Supplement_1): 5543.

https://doi.org/10.1182/blood-2019-131923

Published: 2019

Journal Articles

Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance

Rafael Renatino-Canevarolo, PhD, Praneeth Reddy Sudalagunta, PhD, Maria D Coelho Siqueira Silva, MSc, Mark B. Meads, PhD, Alexandre Tungesvik, MD, Gabriel De Avila, Alugubelli Raghunandan Reddy, Minerva Nong, Jamie Teer, PhD, Eric A. Welsh, PhD, Tint Lwin, MD PhD, Amit Kulkarni, PhD, Hongyue Dai, PhD, William S. Dalton, PhDMD, Kenneth H. Shain, MD PhD, Ariosto Siqueira Silva, PhD

Blood (2019) 134 (Supplement_1): 5544.

https://doi.org/10.1182/blood-2019-128442

Published: 2019

Journal Articles

Phase 1 Study of Bisthianostat, an Orally Efficacious Pan-HDAC Inhibitor: Part Results of Safety, Pharmacokinetics and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma

Hong-Hui Huang, PhD MD, Jian Hou, PhD MD, Yang-Ming Zhang, PhD, Yu-Bo Zhou, PhD, Li Jia, PhD, Fa-Jun Nan, PhD

Blood (2019) 134 (Supplement_1): 5591.

https://doi.org/10.1182/blood-2019-129683

Published: 2019

Journal Articles

An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma

Tim J Peterson, PharmD, Neha Korde, MD, Hani Hassoun, MD, Sham Mailankody, MBBS, Alexander M. Lesokhin, MD, Malin Hultcrantz, MD PhD, Urvi A Shah, MD, Eric L Smith, MD PhD, Sydney X Lu, MD PhD, Heather J Landau, MD, Gunjan L. Shah, MD, Michael Scordo, MD, Oscar B Lahoud, MD, Sergio A Giralt, MD, Ola Landgren, MD PhD

Blood (2019) 134 (Supplement_1): 5554.

https://doi.org/10.1182/blood-2019-124376

Published: 2019

Journal Articles

Residual TP53 Mutation Contributes to Chemoresistance through Clonal Expansion in Acute Myeloid Leukemia

Bowen Yan, PhD, Qinwei Chen, MS, Jianfeng Xu, PhD, Wei Li, PhD, Bing Xu, Suming Huang, PhD, Yi Qiu, PhD

Blood (2019) 134 (Supplement_1): 2731.

https://doi.org/10.1182/blood-2019-127511

Published: 2019

Journal Articles

Panobinostat Potentiates Melphalan-Induced Apoptosis of Myeloma Cells and Minimizes Untoward Side Effects in Multiple Myeloma

Maria Gkotzamanidou, MD PhD, Vassilis L. Souliotis, PhD, Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 2528.

https://doi.org/10.1182/blood-2019-123338

Published: 2019

Journal Articles

Generation, Characterization and Pre-Clinical Drug Evaluation of Patient-Derived Xenograft Models of Pediatric Down Syndrome AML

Sonali Barwe, PhD MSc, E. Anders Kolb, MD, Erin Lynn Crowgey, PhD, Todd E Druley, MD PhD, Anilkumar Gopalakrishnapillai, PhD

Blood (2019) 134 (Supplement_1): 2683.

https://doi.org/10.1182/blood-2019-131050

Published: 2019

Journal Articles

A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)

Guillermo Garcia-Manero, MD, Maciej Kaźmierczak, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Adriano Venditti, Silvia Mappa, MD, Riccardo Spezia, Lionel Ades, MD PhD

Blood (2019) 134 (Supplement_1): 2652.

https://doi.org/10.1182/blood-2019-125924

Published: 2019

Journal Articles

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling

Anthony Quagliano, BS, Anilkumar Gopalakrishnapillai, PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2019) 134 (Supplement_1): 2628.

https://doi.org/10.1182/blood-2019-129198

Published: 2019

Journal Articles

A Phase 1b/2 Study of Chidamide Combined with CHOP in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL)

Yuankai Shi, MD, Lin Gui, MD, Junning Cao, MD, Huilai Zhang, MD, Jun Zhu, MD PhD, Dongmei Ji, MD PhD, Qian Fan, MD, Yuqin Song, MD PhD, Weina Shen, MM, Guiying Bai, MM, Ming-Zhe Han, MD, Shiyu Jiang

Blood (2019) 134 (Supplement_1): 2840.

https://doi.org/10.1182/blood-2019-128078

Published: 2019

Journal Articles

Dissociation of the DNMT3A-HDAC1 Repressor Complex Induces PD-L1 Expression

Jaesung Seo, PhD, Li Li, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 3759.

https://doi.org/10.1182/blood-2019-130339

Published: 2019

Journal Articles

Differentiation Therapy with Novel Epigenetic Inhibitors in Acute Myeloid Leukemia

Edurne San Jose, Naroa Gimenez-Camino, Obdulia Rabal, Estibaliz Miranda, Leire Garate, Fernando Garcia, Ana Alfonso Pierola, MD PhD, Sara Villar, Jose J. Rifon Roca, MD, Antonio Pineda-Lucena, Bruno Paiva, PhD, Javier Muñoz, Jesús San-Miguel, Julen Oyarzabal, PhD, Xabier Agirre, PhD, Felipe Prósper, MD PhD

Blood (2019) 134 (Supplement_1): 3762.

https://doi.org/10.1182/blood-2019-125578

Published: 2019

Journal Articles

Combination of Chidamide with the CHOEP Regimen in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Prospective, Multicenter, Single-Arm, Phase 1b/2 Trial

Blood (2019) 134 (Supplement_1): 4036.

https://doi.org/10.1182/blood-2019-129305

Published: 2019

Journal Articles

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators

Yuxuan Liu, PhD, Jole Fiorito, PhD, Yulissa Gonzalez, Brian Estrella, PhD, Elisa Calcagno, PhD, Elisa Zuccarello, PhD, Howook Hwang, PhD, Barry Honig, PhD, Shixian Deng, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD, Ottavio Arancio, PhD, Jennifer E Amengual, MD

Blood (2019) 134 (Supplement_1): 4068.

https://doi.org/10.1182/blood-2019-125983

Published: 2019

Journal Articles

A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax in Patients with Relapsed/Refractory (R/R) Lymphoma

Anas Younes, MD, Connie Lee Batlevi, MD PhD, Jonathon B. Cohen, MDMS, Sven de Vos, MD PhD, Daniel J. Landsburg, MD, Zaw Win Myint, MD, Krish Patel, MD, Tycel J. Phillips, MD, Sonali M. Smith, MD, Jason R. Westin, MD, Anna W Ma, MS, Dena Grayson, MD PhD, Reinhard von Roemeling, MD, Stefan K. Barta, MD MRCP, MS

Blood (2019) 134 (Supplement_1): 4104.

https://doi.org/10.1182/blood-2019-128857

Published: 2019

Journal Articles

Associations between Microrna Expression, Disease Progression and Ex Vivo Drug Response in Multiple Myeloma

Romika Kumari, PhD, Ashwini Kumar, MRes, Alun Parsons, Minna Suvela, MSC, Juha Lievonen, MD, Raija Helena Silvennoinen, MD PhD, Pekka Anttila, MD, Caroline A Heckman, PhD

Blood (2019) 134 (Supplement_1): 3069.

https://doi.org/10.1182/blood-2019-128181

Published: 2019

Journal Articles

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

Takeshi Harada, MD PhD, Asuka Oda, Hiroto Ohguchi, MD PhD, Yohann Grondin, PhD, Hirofumi Tenshin, DDS, PhD, Masahiro Hiasa, DDS, PhD, Jumpei Teramachi, Masahiro Oura, MD, Kimiko Sogabe, MD, Shiro Fujii, MD PhD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Kumiko Kagawa, MD PhD, Shuji Ozaki, MD PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Masahiro Abe, MD PhD

Blood (2019) 134 (Supplement_1): 3111.

https://doi.org/10.1182/blood-2019-127679

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms

Dual Epigenetic Agents Plus Rituximab-Gemcitabine-Oxaliplatin As a Salvage Treatment in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance

Phase 1 Study of Bisthianostat, an Orally Efficacious Pan-HDAC Inhibitor: Part Results of Safety, Pharmacokinetics and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma

An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma

Residual TP53 Mutation Contributes to Chemoresistance through Clonal Expansion in Acute Myeloid Leukemia

Panobinostat Potentiates Melphalan-Induced Apoptosis of Myeloma Cells and Minimizes Untoward Side Effects in Multiple Myeloma

Generation, Characterization and Pre-Clinical Drug Evaluation of Patient-Derived Xenograft Models of Pediatric Down Syndrome AML

A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling

A Phase 1b/2 Study of Chidamide Combined with CHOP in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL)

Dissociation of the DNMT3A-HDAC1 Repressor Complex Induces PD-L1 Expression

Differentiation Therapy with Novel Epigenetic Inhibitors in Acute Myeloid Leukemia

Combination of Chidamide with the CHOEP Regimen in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Prospective, Multicenter, Single-Arm, Phase 1b/2 Trial

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators

A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax in Patients with Relapsed/Refractory (R/R) Lymphoma

Associations between Microrna Expression, Disease Progression and Ex Vivo Drug Response in Multiple Myeloma

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only